Castration resistant prostate cancer remains a major clinical burden and novel therapeutic options are urgently required to improve survival.
Tasquinimod is an orally administered quinoline-3-carboxamide with potent antiangiogenic and antitumorigenic action that has shown promise in the treatment of advanced prostate cancers. This review explores both preclinical and clinical findings to date. In summary, tasquinimod has been shown to demonstrate a potent in vitro and in vivo anticancer action and completed early phase clinical trials have demonstrated good drug tolerance and prolonged progression-free survival. Although Phase III clinical trials are on-going, the findings to date highlight the promise of this drug in the treatment of advanced prostate cancer.
Written by:
Williamson SC, Hartley AE, Heer R. Are you the author?
Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, Tyne and Wear, UK.
Reference: Drug Des Devel Ther. 2013 Mar 21;7:167-74.
doi: 10.2147/DDDT.S31500
PubMed Abstract
PMID: 23662046
UroToday.com Prostate Cancer Section
